Oramed Pharmaceuticals Inc. — Director's Dealing 2024

Jun 10, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2024-06-06

Reporting Person: Reznick Yehuda (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-06-06	Common Stock	A	760	—	Acquired	30560	Direct

Footnotes

F1: Represents a grant of 760 Restricted Stock Units ("RSUs") that will vest in two equal installments on October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.